| 1 |
pathologic complete response
(2712 times)
|
Neoplasms
(1768 times)
|
NAC (421 times)
OS (402 times)
DFS (283 times)
|
0 Predictive diagnosis in breast cancer - Whats new in 2018?
|
| 2 |
pathological response
(118 times)
|
Neoplasms
(75 times)
|
OS (17 times)
NAC (14 times)
DFS (10 times)
|
1998 [Coexistence of ovarian adenocarcinoma with tubal pregnancy and plano-epithelial cervical cancer of uterus].
|
| 3 |
pathologic CR
(25 times)
|
Neoplasms
(17 times)
|
CR (14 times)
cCR (9 times)
PR (7 times)
|
1996 [Treatment of advanced testis cancer with a high dose chemotherapy regimen (PVeBV)].
|
| 4 |
pathological remission
(12 times)
|
Neoplasms
(6 times)
|
MALT (5 times)
AIO (2 times)
DCX (2 times)
|
2001 [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
|
| 5 |
pathologically confirmed complete remissions
(3 times)
|
General Surgery
(1 time)
|
EC (1 time)
FIGO (1 time)
GRCSG (1 time)
|
1988 Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy.
|
| 6 |
patients with major histopathological response
(3 times)
|
Neoplasms
(2 times)
|
cCR (1 time)
HT (1 time)
Ir-192 HDR (1 time)
|
1994 Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
|
| 7 |
Pathologic response was denoted as complete
(2 times)
|
Nuclear Medicine
(1 time)
|
DFS (1 time)
LABC (1 time)
NeoChemo (1 time)
|
2010 Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
|
| 8 |
pathologic response: complete
(2 times)
|
Neoplasms
(1 time)
|
5-FU (1 time)
DT (1 time)
LABC (1 time)
|
2010 Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
|
| 9 |
Patients with complete response
(2 times)
|
Molecular Biology
(1 time)
|
DSB (1 time)
ICT (1 time)
LRR (1 time)
|
2016 Local Recurrence in the Lateral Lymph Node Compartment: Improved Outcomes with Induction Chemotherapy Combined with Multimodality Treatment.
|
| 10 |
polymerase chain reaction
(2 times)
|
Antineoplastic Agents
(1 time)
|
Ab (1 time)
CAP (1 time)
MBE (1 time)
|
2009 Acinetobacter baumannii: emergence of four strains with novel bla(OXA-51-like) genes in patients with diabetes mellitus.
|
| 11 |
improve complete response rates
(1 time)
|
Neoplasms
(1 time)
|
CSS (1 time)
DFS (1 time)
OS (1 time)
|
2013 Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
|
| 12 |
P wave complexity ratio
(1 time)
|
Cardiology
(1 time)
|
AF (2 times)
CABG (1 time)
PD (1 time)
|
2004 Preoperative electrocardiographic risk assessment of atrial fibrillation after coronary artery bypass grafting.
|
| 13 |
para-cresol
(1 time)
|
Biophysics
(1 time)
|
PH (1 time)
|
2013 Molecular-level understanding of ground- and excited-state O-H...O hydrogen bonding involving the tyrosine side chain: a combined high-resolution laser spectroscopy and quantum chemistry study.
|
| 14 |
pathologic complete remission response
(1 time)
|
Neoplasms
(1 time)
|
BC (1 time)
|
2020 Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study.
|
| 15 |
pathologic examination of the resection specimen
(1 time)
|
General Surgery
(1 time)
|
CI (1 time)
DR (1 time)
EAC (1 time)
|
2015 Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
|
| 16 |
Pathologic response to chemotherapy
(1 time)
|
Neoplasms
(1 time)
|
AA (1 time)
HR (1 time)
OS (1 time)
|
2015 Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.
|
| 17 |
Pathologic response to induction was complete
(1 time)
|
General Surgery
(1 time)
|
NSCLC (1 time)
|
2014 Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet.
|
| 18 |
pathological clinical response
(1 time)
|
Neoplasms
(1 time)
|
FCGR2A (1 time)
|
2015 FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
|
| 19 |
pathological complete primary tumor response
(1 time)
|
Neoplasms
(1 time)
|
HR (1 time)
pN0 (1 time)
|
2010 [Role of lymph node irradiation in breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy: the Rene-Huguenin Cancer Center experience].
|
| 20 |
pathological complete response in breast and lymph nodes
(1 time)
|
Breast Neoplasms
(1 time)
|
---
|
2016 Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
|
| 21 |
pathological complete response to chemotherapy
(1 time)
|
Neoplasms
(1 time)
|
MPG (1 time)
NLR (1 time)
PLR (1 time)
|
2020 Neutrophils-to-lymphocytes, lymphocytes to-monocytes and platelets-to-lymphocytes ratios - predictive biomarkers for response to neoadjuvant chemotherapy in breast cancer.
|
| 22 |
pathological evidence of disease in the breast
(1 time)
|
Neoplasms
(1 time)
|
cCR (1 time)
|
2002 The surgical management of patients following neoadjuvant chemotherapy for locally advanced breast cancer.
|
| 23 |
Pathological response rates were as follows: Complete
(1 time)
|
Neoplasms
(1 time)
|
---
|
2006 Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma.
|
| 24 |
Pathological response was classified as no residual tumor
(1 time)
|
Gynecology
(1 time)
|
LACA (1 time)
NACT (1 time)
TAP (1 time)
|
2014 Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma.
|
| 25 |
pathological response was classified into either a complete response
(1 time)
|
Diagnostic Imaging
(1 time)
|
ADC (1 time)
DWI (1 time)
MRI (1 time)
|
2015 Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
|
| 26 |
Pathological responses were considered complete
(1 time)
|
Neoplasms
(1 time)
|
npCR (1 time)
|
2005 Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
|
| 27 |
Pathological tumor regression
(1 time)
|
Gastroenterology
(1 time)
|
CRT (1 time)
|
2020 Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series.
|
| 28 |
pathologically after surgery
(1 time)
|
Gastroenterology
(1 time)
|
cCR (1 time)
ESCP (1 time)
|
2018 Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery.
|
| 29 |
pathologically confirmed CR
(1 time)
|
Neoplasms
(1 time)
|
CRs (1 time)
EAP (1 time)
PRs (1 time)
|
1989 Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.
|
| 30 |
pathologically diagnosed as necrosis/fibrosis or teratoma
(1 time)
|
Urology
(1 time)
|
psCR (1 time)
RPLND (1 time)
|
1999 [Clinical study of retroperitoneal lymph node dissection for patients with advanced germ cell tumors].
|
| 31 |
Pathologically, complete response was confirmed
(1 time)
|
Antineoplastic Agents
(1 time)
|
---
|
2007 [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
|
| 32 |
patients achieve a clinical complete response
(1 time)
|
Gastroenterology
(1 time)
|
AIOM (1 time)
DFS (1 time)
GRADE (1 time)
|
2020 Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM).
|
| 33 |
patients underwent ALND after chemotherapy, and complete axillary response
(1 time)
|
General Surgery
(1 time)
|
ALND (1 time)
FDG (1 time)
NAC (1 time)
|
2013 Early assessment of axillary response with ⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
|
| 34 |
Patients were classified into complete
(1 time)
|
General Surgery
(1 time)
|
EAC (1 time)
|
2017 Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
|
| 35 |
patients, mainly with chemotherapy induced surgicopathological complete remission
(1 time)
|
Cardiology
(1 time)
|
---
|
2001 Small cell lung cancer I--III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy.
|
| 36 |
possible complete response
(1 time)
|
Neoplasms
(1 time)
|
OS (1 time)
RT (1 time)
SRT (1 time)
|
2019 Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial.
|
| 37 |
postchemoradiotherapy
(1 time)
|
Neoplasms
(1 time)
|
---
|
2005 Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
|
| 38 |
Primary endpoints were efficacy, determined by histopathological complete response
(1 time)
|
Neoplasms
(1 time)
|
AEs (1 time)
cetux-RT (1 time)
SAEs (1 time)
|
2014 Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
|
| 39 |
profile showed no significant differences between complete
(1 time)
|
Natural Science Disciplines
(1 time)
|
LARC (1 time)
nCRT (1 time)
NT (1 time)
|
2019 Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response.
|
| 40 |
proportional odds structure
(1 time)
|
Statistics as Topic
(1 time)
|
CR (1 time)
KM (1 time)
|
2015 Sparse kernel machine regression for ordinal outcomes.
|
| 41 |
proven complete remission
(1 time)
|
Neoplasms
(1 time)
|
cT (1 time)
HRS (1 time)
|
2003 Remission rates in breast cancer treated with preoperative chemotherapy and radiotherapy.
|
| 42 |
proven histologically at laparotomy
(1 time)
|
Neoplasms
(1 time)
|
CR (1 time)
ORR (1 time)
PR (1 time)
|
1997 Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
|
| 43 |
pulmonary metastases as either complete lack of residual lesions
(1 time)
|
Hematology
(1 time)
|
CI (1 time)
CR (1 time)
CWS (1 time)
|
2017 The prognostic value of early radiographic response in children and adolescents with embryonal rhabdomyosarcoma stage IV, metastases confined to the lungs: A report from the Cooperative Weichteilsarkom Studiengruppe (CWS).
|
| 44 |
therapy.Pathologic complete response
(1 time)
|
General Surgery
(1 time)
|
CEA (1 time)
|
2010 [Clinical pathologic factors predicting tumor response after preoperative neoadjuvant therapy for rectal cancer].
|
A Search Service for Abbreviation / Long Form